Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 399 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Testosterone Clear all

Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions: HER2Bi-Armed Activated T Cells, Laboratory Biomarker Analysis, Pembrolizumab; Biological · Other
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 19 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions: Enzalutamide, Venetoclax; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Hypogonadism, Male
Interventions: Clomiphene; Drug
Lead sponsor: Phoenix VA Health Care System; Federal
Eligibility: 30 Years to 70 Years · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Contraception
Interventions: Testosterone, Nestorone®; Drug
Lead sponsor: Premier Research; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Torrance, California • Seattle, Washington

Conditions: Healthy, Men, Male Contraception
Interventions: Nestorone + Testosterone Combination Gel; Drug
Lead sponsor: Premier Research; Other
Eligibility: 18 Years to 50 Years
Enrollment: 420 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 9
States / cities: Sacramento, California • Torrance, California • Denver, Colorado + 6 more

Conditions: Vaginitis, Dyspareunia, Breast Neoplasms
Interventions: Testosterone propionate; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 2
States / cities: Pawtucket, Rhode Island • Burlington, Vermont

Conditions: Testosterone Deficiency
Interventions: Jatenzo; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Testosterone Transdermal System, Placebo; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 20 Years to 70 Years · Female only
Enrollment: 562 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Metastatic Prostate Cancer
Interventions: High dose testosterone; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 17
States / cities: Aurora, Colorado • West Haven, Connecticut • Gainesville, Florida + 14 more

Conditions: Ligament Tear Knee
Interventions: Oxandrolone, Placebo; Drug
Lead sponsor: George F. Hatch; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Contraception, Hypogonadism
Interventions: Acyline, Testosterone, Finasteride; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Health Services for Transgender Persons, Transgender Persons
Interventions: Testosterone injection, PedsQL questionnarie, Masculinizing effects questionnaire, Medication experience questionnaire; Drug · Behavioral · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 14 Years to 19 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Hypogonadism, Male
Interventions: LPCN 1021; Drug
Lead sponsor: Lipocine Inc.; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 16
States / cities: Birmingham, Alabama • Aventura, Florida • Coral Gables, Florida + 13 more

Conditions: Prostate Cancer, Hypogonadism, Male
Interventions: Testosterone cypionate; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Testosterone Greater Than 150 ng/dL
Interventions: Daratumumab, FMS Inhibitor JNJ-40346527, Radical Prostatectomy; Biological · Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IVB Prostate Cancer AJCC v8
Interventions: Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981, Nivolumab; Drug · Biological
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Detroit, Michigan

Conditions: Traumatic Injury
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 90 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Transgender, Transgenderism
Interventions: Not listed
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 12 Years to 30 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Hypogonadism
Interventions: Testosterone enanthate auto-injector; Combination Product
Lead sponsor: Antares Pharma Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 28
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 25 more

Conditions: Hypoactive Sexual Desire Disorder
Interventions: transdermal testosterone gel 1%, placebo gel; Drug
Lead sponsor: BioSante Pharmaceuticals; Industry
Eligibility: 30 Years to 66 Years · Female only
Enrollment: 626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 98
States / cities: Hoover, Alabama • Huntsville, Alabama • Mobile, Alabama + 91 more

Conditions: Hypogonadal Males
Interventions: ABT-SLV361, placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 80 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Fort Myers, Florida

Conditions: Testosterone, Placebos
Interventions: Testosterone, Placebo; Drug
Lead sponsor: Robert Josephs; Other
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Diabetes Mellitus Type 2
Interventions: androgel, androgel 10g, placebo; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 35 Years to 75 Years · Male only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Contraception
Interventions: Testosterone Enanthate, Dutasteride, placebo sesame oil; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Clomid in Men With Low Testosterone With and Without Prior Treatment

Study of the Safety, and Sperm and Gonadotropin Suppression of a Contraceptive Gel in Normal Men

Study of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception

Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer.

Patient Satisfaction After Switching to Oral Testosterone Undecanoate

Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

Oxandrolone Multiligament Knee

ORAL T-6: Oral Androgens in Man-6

Comparing Subcutaneous Testosterone to Intramuscular Testosterone in Gender Affirming Care of Transgender Male Adolescents

Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men

Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance

Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer

ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

Characterization of the Early Sex Hormone Milieu Post Injury and Relationship With Resuscitation Requirements and Coagulopathy

Cardiometabolic Health in Transgender Males

Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism

Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

Study of the Safety, Tolerability and Pharmacokinetics of Testosterone Undecanoate in Hypogonadal Males.

A Multinomial Process Model of Moral Judgment

Effect of Androgel on Type 2 Diabetic Males With Hypogonadism

Oral Androgens in Man-4: (Short Title: Oral T-4)